Spark Biomedical, Inc. Granted $2.49M from the National Institutes of Health for a Clinical Trial Looking at Extended Use of Wearable Neurostimulation in Opioid Use Disorder Treatment
November 16, 2021 11:00 ET
|
Spark Biomedical
Dallas, TX, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc. has been helping patients overcome acute opioid withdrawal using its Sparrow Therapy System — Transcutaneous Auricular...
Spark Biomedical, Inc enlists the expertise of former Deputy Secretary of the U.S. Department of Health and Human Services, Eric D. Hargan, to help make novel opioid withdrawal treatment more accessible and affordable for patients
November 04, 2021 10:25 ET
|
Spark Biomedical
Dallas, TX, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc, a leader in wearable neurostimulation for opioid withdrawal relief, today announced the Company will join forces with Eric D....
Sierra Tucson Combats Opioid Withdrawal Using Groundbreaking Wearable Neurostimulation Therapy
May 26, 2021 11:19 ET
|
Spark Biomedical
TUCSON, AZ, May 26, 2021 (GLOBE NEWSWIRE) -- Sierra Tucson, a nationally respected provider of comprehensive residential services for adults struggling with substance use disorders and other...
Bux Pain Management Treats First Commercial Patient in the Nation Using Spark Biomedical’s Sparrow Therapy System
February 03, 2021 15:34 ET
|
Spark Biomedical
Danville, KY, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Dr. Anjum Bux, a leading expert in pain management, was the first in the nation to successfully treat commercial patients using Transcutaneous...
Spark Biomedical’s Sparrow Therapy System™ receives FDA Clearance for Opioid Withdrawal Relief in Adults
January 04, 2021 16:38 ET
|
Spark Biomedical
Dallas, TX, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc. announced today that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance to The Sparrow Therapy System, a...
Spark Biomedical Receives FDA Breakthrough Device Designation for Infant Transcutaneous Auricular Neurostimulation (tAN™) Device, The Roo™ System
December 15, 2020 14:14 ET
|
Spark Biomedical
Dallas, Texas, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc. announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Roo System: a...
Nine Foremost Pain Management Physicians Join the Spark Biomedical, Inc. Medical Advisory Board
August 28, 2020 09:30 ET
|
Spark Biomedical
Dallas, Texas, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Spark Biomedical, developer of the Sparrow ™ Therapy System — a discrete, wearable, over-the-ear, medical device designed for opioid withdrawal...
Neurostimulation Clinical Trial Shows Promising Initial Results in Easing Opioid Withdrawal Symptoms in Newborns
August 05, 2020 11:14 ET
|
Spark Biomedical
Dallas, Texas, Aug. 05, 2020 (GLOBE NEWSWIRE) -- While instances of Neonatal Opioid Withdrawal Syndrome (NOWS) are still on the rise, and the eyes of the nation remain focused on a pandemic, the...